Curetis

Curetis and BGI subsidiary MGI Tech plan to develop NGS-based diagnostics for microbial infections on the MGISeq instrument for the Chinese market. 

The firms will use MGI's sequencing technology and Curetis' sample prep platform and antibiotic resistance database to develop IVDs, initially for China.

The company also announced a deal to provide in-house testing services to drugmaker Biotest, as well as changes to its management team.

The Inhale project is assessing respiratory disease tests on Oxford Nanopore's MinIon and PCR platforms from Curetis and BioMérieux's BioFire Diagnostics.

The company also disclosed that it has modified the US regulatory package for its lower respiratory tract diagnostic panel after discussions with the FDA.

The new panel is able to detect up to 130 pathogens that cause severe abdominal infections, such as appendicitis and acute pancreatitis. 

The company attributed the decline in part to nonrecurring sales of its Unyvero molecular diagnostic system to partners for clinical trials and regulatory clearances.

Ares plans to use the GEAR database to discover new markers of antibiotic resistance and will eventually develop it as an interpretation service. 

Curetis' new subsidiary will focus on using a recently acquired database of bacterial genome sequences to identify novel antibiotic resistance markers. 

Curetis recently completed a clinical trial that compared the panel to both microbiology and individual PCR testing plus sequencing.

Pages

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.